Status:
COMPLETED
A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis
Lead Sponsor:
Dermatology Specialists Research
Collaborating Sponsors:
Novartis
Conditions:
Seborrheic Dermatitis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is an exploratory study to determine effectiveness of Elidel for the treatment of seborrheic dermatitis
Detailed Description
This is a 4 week study for patients 18 and older to compare the efficacy and safety of pimecrolimus cream 1% twice daily and ketaconazole cream 2 % twice daily for the treatment of seborrheic dermatit...
Eligibility Criteria
Inclusion
- Must be 18 or older and sign written informed consent.
- Must be wiling and able to comply with protocol.
- Must have active seborrheic dermatitis of the face.
Exclusion
- No history of overt bacterial, viral or fungal infection of the head/neck.
- No history or presence of compromising dermatosis elsewhere on the skin
- No Parkinson's disease, HIV, infections or disorders of the central nervous system
- No actinically damaged skin
Key Trial Info
Start Date :
May 7 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 27 2009
Estimated Enrollment :
113 Patients enrolled
Trial Details
Trial ID
NCT00403559
Start Date
May 7 2007
End Date
February 27 2009
Last Update
March 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dermatology Specialists
Louisville, Kentucky, United States, 40202